People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| FORE US Bio Inc. | — | Biotechnology | Series C | $99.5M | $243.5M | 2023 |
| Atox Bio Inc. | — | Biotechnology | Series B | $35.1M | $1.3B | 2017 |
Matthew Foy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Foy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Erez Chimovits | 2 | 7 |
| Michal Silverberg | 1 | 7 |
| Terry Gould | 1 | 6 |
| Casper Breum | 1 | 5 |
| Dieter Weinand | 1 | 4 |
| Daniel Burgess | 1 | 4 |
| Chandra Leo | 1 | 3 |
| Kim Blackwell | 1 | 3 |
| Giovanni Mariggi | 1 | 2 |
| Arnon Aharon | 1 | 2 |
| Dan Teleman | 1 | 2 |
| Michael Byrnes | 1 | 2 |
| William Hinshaw | 1 | 2 |
| Meenu Chhabra Karson | 1 | 2 |
| Roberto De Ponti | 1 | 2 |
| Jonathan Tobin | 1 | 2 |
| Newton Becker | 1 | 1 |
| Jeff Sacher | 1 | 1 |
| Matthew Ros | 1 | 1 |
| MEIR BATITO | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.